Kelly Davio


In Updated Draft Evidence Report on RA, ICER Changes Course on Assessing JAK Inhibitors

October 11, 2019

The Institute for Clinical and Economic Review (ICER), a nonprofit health technology assessment body, has issued an updated report on treatments for rheumatoid arthritis (RA) in which it says that the Janus kinase (JAK) inhibitor upadacitinib has a marginal clinical benefit over adalimumab and an "incremental cost-utility ratio falling below commonly cited thresholds.”

ISOPP Releases Position on Biosimilars, Voices Opposition to Treating Biosimilars as Interchangeable

October 11, 2019

The International Society of Oncology Pharmacy Practitioners (ISOPP), which convened in London, United Kingdom, this week for its 18th international symposium on oncology pharmacy practice, has issued a new global position statement on biosimilars in therapeutic and supportive oncology.

Report Points to Room for Improvement in the European Biosimilars Market

October 10, 2019

A new KPMG report, commissioned by generic and biosimilar trade group Medicines for Europe, identifies some of the features of drug procurement in hospitals in different countries in Europe, explains how they impact biosimilar uptake, and gives recommendations to help biosimilars play a role in the strong—and growing—need to reduce spending in health systems.

Samsung Bioepis' Etanercept Biosimilar Performs in Real-World Treatment of Psoriasis

October 09, 2019

In treating patients with moderate to severe psoriasis, Samsung Bioepis’ etanercept biosimilar, approved in the European Union as Benepali and in the United States as Eticovo, was shown to be effective in a registry study.

For Price Hikes Without New Data, 3 Drugs With Approved Biosimilars Are Key Offenders, Says ICER

October 09, 2019

The Institute for Clinical and Economic Review (ICER) has issued its first annual report on unsupported price increases for US drugs. The report found that 3 brand-name biologics that have FDA-approved biosimilars—adalimumab, rituximab, and pegfilgrastim—have had significant price increases that were not supported by new clinical evidence.

New Anti-VEGF Agent, Brolucizumab, Cleared by FDA to Treat AMD

October 08, 2019

Even as biosimilars of anti–vascular endothelial growth factor (anti-VEGF) agents are coming to market and advancing through the pipeline, a new agent that may have substantial benefits for patients with wet age-related macular degeneration (AMD) has been approved by the FDA: brolucizumab, which sponsor Novartis will sell as Beovu.

Pediatric Patients and Their Families Report Unique Concerns When It Comes to Biosimilar Switching

October 07, 2019

According to the authors, while many anticipated that most major concerns about the switch to biosimilar adalimumab would relate to safety and efficacy, more prevalent concerns were related to device type, the presence of a citrate, or the color of the product.

UK Opposition Party Proposes Compulsory Licensing to Develop Cheaper Drugs

October 05, 2019

The Labour party, the United Kingdom’s official opposition party, revealed during a conference that it plans to reduce the cost of drugs by setting up a government-owned generic drug manufacturer that would supply medicine to the National Health Service and by employing compulsory licensing to use drug makers’ intellectual property to develop generics.